Important considerations when contemplating endoscopic resection of undifferentiated-type early gastric cancer

Jie-Hyun Kim

Jie-Hyun Kim, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, South Korea

Author contributions: Kim JH analyzed the literature and wrote the manuscript.

Conflict-of-interest statement: The author has no conflict of interest to report.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Jie-Hyun Kim, MD, PhD, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-gu, Seoul 135-720, South Korea. otilia94@yuhs.ac
Telephone: +82-2-20193505
Fax: +82-2-34633882

Received: June 3, 2015
Peer-review started: June 5, 2015
First decision: August 31, 2015
Revised: September 11, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: January 21, 2016

Abstract

Endoscopic resection (ER) of undifferentiated-type early gastric cancer (UD-EGC) has a lower curative resection (CR) rate than does ER of differentiated-type EGC (D-EGC). However, a low CR rate does not mean that it is unreasonable to schedule ER of UD-EGC. If ER is in fact curative, the long-term outcomes including survival rate are excellent. Quality of life is good because maximal stomach preservation is possible. However, UD-EGC and D-EGC differ histologically. Thus, when ER is contemplated to treat UD-EGC, a careful approach employing strict criteria is essential because the biology of UD-EGC and D-EGC differ.

Key words: Early gastric cancer; Undifferentiated; Endoscopic resection; Lymph node metastasis

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: If endoscopic resection (ER) of undifferentiated-type early gastric cancer (UD-EGC) is in fact curative, the long-term outcomes are excellent. However, when ER is contemplated to treat UD-EGC, a careful approach employing strict criteria is essential because the biology of UD-EGC and differentiated-type EGC (D-EGC) differ. In this review, we will discuss the important points to perform ER in UD-EGC according to the data known so far.

INTRODUCTION

Traditionally, the standard treatment for early gastric cancer (EGC) is surgery. However, more recently, endoscopic resection (ER) has become a standard local treatment for some patients with EGC who lack lymph node metastasis (LNM)

[1]. Initially, ER was used to treat differentiated-type EGC (D-EGC) with a < 2-cm-
January 21, 2016 | Volume 22 | Issue 3 | WJG | www.wjgnet.com

Kim JH. Early gastric cancer with undifferentiated histology

Histological diagnosis prior to treatment is important, especially if ER is contemplated. Furthermore, a change from D-EGC status on prior biopsy to UD-EGC status at the time of ER is critical in terms of a decision to perform additional surgery after ER and to predict prognosis.[12,13]. In previous studies, about 15% to 18% of patients with UD-EGC diagnosed after ER exhibited differentiated histology on biopsy prior to ER.[12,13]. A tumor diameter of > 2 cm and bodily location predict the histological features of UD-EGC.[12-14]. A UD-EGC exhibiting differentiated histology on biopsy is more aggressive and associated with a lower curative resection rate than is a UD-EGC, consistent with the biopsy pathology.[12-14]. When precise histological diagnosis prior to ER is required, magnifying endoscopy (ME) with narrow-band imaging (NBI) is helpful. Additionally, the actual biopsy site may be more important than the number of biopsies taken. A previous study featuring histopathological mapping and evaluation of the endoscopic appearance of UD-EGCs that exhibited differentiated histology on prior biopsy found that the zone of transition from differentiated to undifferentiated-type histology frequently occurred in one or two peripheral regions of the lesion.[12]. Thus, biopsy of several peripheral regions may aid in the diagnosis of undifferentiated-type histology prior to ER.[12].

Undifferentiated-type histology

ER of EGCs

The risk of LNM is the most important factor to consider when contemplating ER of EGCs.[17]. Thus, the indications for ER are the absence of risk factors associated with LNM and include consideration of the histological status of the EGC. The relevant histological classifications include those of the World Health Organization (WHO), Lauren, and Japanese experts.[1,7,15,16]. Many studies have found that the biological behaviors of EGC vary according to histological differentiation.[17,18].

ER has been performed with reference to the Japanese classification, which simply categorizes patients with EGC into those with differentiated or undifferentiated-type histology. In this classification, undifferentiated adenocarcinoma[19] is a cancer that lacks glands and includes poorly differentiated adenocarcinoma (PDA), signet ring cell carcinoma (SRC), and mucinous adenocarcinoma (MA) (as does the WHO system). PDA and MA are associated with higher LNM rates than are EGCs of other histological types, and the SRC form of EGC is associated with relatively less LNM than are EGCs of other histologies.[20-23]. Thus, biological behaviors such as LNM differ among the histopathological subtypes of UD-EGC.

However, when ER is performed with reference to current indications, the clinical outcomes of PDA and SRC patients do not differ significantly.[6,10]. The first report on the use of ER to treat UD-EGCs of various histological subtypes found no instance of either local recurrence or distant metastasis in patients with either PDA or SRC if curative resection (CR) was attained.[10]. This result was validated on long-term follow-up (Figure 1).[9]. Therefore, the current criteria for CR of UD-EGC can be applied to both patients with PDA and those with SRC, who enjoy good long-term outcomes.

The current indications for ER do not include EGC of mixed histology. As mentioned above, the Japanese classification categorizes EGCs into only gastric cancers of differentiated or undifferentiated-type histology. However, many studies have found that EGCs of mixed histologies exhibit more aggressive clinicopathological behaviors than do EGCs of non-mixed histologies.[18,24-26]. We also found that SRC mixed histology, defined as an adenocarcinoma with a minor component less than 50% of the SRC, is associated with more LNM than are EGCs of other histologies.[18]. We therefore explored the clinicopathological behaviors of EGCS of mixed histology to determine whether new ER criteria are required (manuscript submitted).

We measured LNM rates by all recognized types of mixed histology as follows: (1) the mixed type as non-homogenous mixtures of the Lauren classification; (2) the mixed type of the Lauren classification divided into the differentiated dominant and the undifferentiated dominant mixed types[24]; and (3) SRC mixed histology identified in our previous study.[18]. As found previously, the LNM rates were higher in patients with EGC with all types of mixed histology than in those with pure types of EGC. When analyzing within the current ER criteria, however, LNM was not observed. Thus, this need for new criteria when ER is contemplated for patients with EGCs of mixed histologies has not been identified until now. Further studies are required. Two prior works reported different outcomes after ER of EGCs of
Kim JH. Early gastric cancer with undifferentiated histology

<table>
<thead>
<tr>
<th>CR 37 (45.1%)</th>
<th>Non-CR 45 (54.9%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metachronous 2 (5.1%)</td>
<td>No 10 (22.2%)</td>
</tr>
<tr>
<td>ER 1 (50.0%)</td>
<td>Op 1 (50.0%)</td>
</tr>
<tr>
<td>CTx 1 (33%)</td>
<td>Expire 1</td>
</tr>
<tr>
<td>No recurrence</td>
<td></td>
</tr>
<tr>
<td>Expire 1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CR 78 (61.4%)</th>
<th>Non-CR 49 (38.6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metachronous 3 (3.8%)</td>
<td>No 6 (12.2%)</td>
</tr>
<tr>
<td>Op 2 (67%)</td>
<td></td>
</tr>
<tr>
<td>Expire 1</td>
<td></td>
</tr>
<tr>
<td>Expire 1</td>
<td></td>
</tr>
<tr>
<td>No recurrence</td>
<td></td>
</tr>
<tr>
<td>Expire 1</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1  Follow-up outcomes after endoscopic resection of undifferentiated-type early gastric cancer. The numbers in the boxes are the numbers of cases. CR: Curative resection; PDA: Poorly differentiated adenocarcinoma; SRC: Signet ring cell carcinoma; APC: Argon plasma coagulation; ER: Endoscopic resection. Taken with permission from Surg Endosc 2014; 28: 2627-2633.

mixed histology\[^{27,28}\]. One found a lower CR rate and more local recurrence after ER of EGCs of mixed than pure histology\[^{27}\]. However, the other study reported favorable long-term outcomes (including the absence of LNM and extragastric recurrence) during follow-up after ER of EGCs of mixed histology that met the curative ER criteria\[^{28}\].

**ER OF UNDIFFERENTIATED-TYPE EGCS**

If CR is attained, the long-term outcomes after ER of UD-EGC are favorable in terms of local recurrence, LNM, distant metastasis, and survival\[^{6,29-33}\]. However, the CR rates have historically been low (30%–80%)\[^{6,10,29,32,34}\]. The principal reason why the CR rate differs between PDA and SRC (although the long-term outcomes do not)\[^{6,10}\] is that non-CR is associated with a vertical cut-end positive status in patients with PDA and a lateral cut-end positive status in patients with SRC\[^{6,10}\].

In terms of non-CR of PDA, prediction of tumor depth before treatment is difficult. Although pretreatment evaluation via endoscopic ultrasonography (EUS) may suggest that the lesions are confined to the mucosa, the lesions may in fact have attained the submucosa (Figure 2)\[^{10,35}\]. Such observations suggest that pretreatment EUS evaluation of the invasion depth may often underestimate such depth in patients with PDA, consistent with data of a previous study in which PDA histological features were significantly associated with understaging of the invasion depth upon multivariate analysis\[^{10,35}\]. Therefore, the possibility of depth underestimation upon EUS should be considered prior to ER of PDA. Strict EUS criteria for submucosal invasion should be established to avoid T-stage underestimation for achieving CR in PDA\[^{10,35}\].

With respect to non-CR of SRC, it is difficult to define the extent of the lesion. ME with NBI has been used in efforts to precisely define the lateral extent of EGC\[^{6,36,37}\]. However, several studies found that such predictions were inaccurate in patients with UD-EGC, but not in those with D-EGC\[^{6,37,38}\]. Yao et al\[^{37}\] suggested that the strategy should vary by the histological type of EGC (D- vs UD-EGC). For the latter type of tumor, the margins should be determined by biopsy of apparently non-cancerous tissue surrounding the lesion and histological confirmation of the absence of any cancerous invasion\[^{38}\]. In other words, it is difficult to precisely define the lateral margins of UD-EGCs; pathological confirmation is required. Surface ME with NBI will not detect any cancer-specific, irregular microvascular or microsurface pattern if the cancer cells have infiltrated the lamina propria, perhaps to the depth of the glandular neck\[^{38}\]. The origin of SRC reportedly differs from that of other gastric adenocarcinomas\[^{39}\]. Tubule neck dysplasia (TND) may be a precursor lesion of SRC\[^{39}\]. TND can spread upward toward the foveolar surface and possibly downward to the gastric glands\[^{39}\]. Thus, the gastric mucosal surface epithelium in patients with early-stage SRC may appear to be largely intact despite the presence of cancer cells in the lamina propria. It
may be useful to define ER subgroups of SRC based on intramucosal spreading patterns such as epithelial spread, and not simply to determine resection margins via endoscopy or biopsy. Indeed, we examined the intramucosal spreading patterns of the SRC type of EGC reported previously, and identified (for example) both expanding (epithelial spread) and infiltrative (subepithelial spread) subtypes\(^{[11]}\). The proportion of infiltrative spread was higher in lateral cut-end-positive than -negative early-stage SRCs (Figures 3 and 4)\(^{[40]}\). We also found that the surrounding mucosal pattern was useful to define the type of intramucosal spread in early-stage SRCs (Figures 3 and 4)\(^{[40]}\). The mucosa surrounding infiltrative lesions more commonly exhibited atrophy and intestinal metaplasia\(^{[40]}\), indicating that the mucosa may be an important mechanical barrier to tumor spread in patients with early-stage SRC\(^{[40]}\). This is in line with the fact that diagnosis of the extent of an undifferentiated-type lesion against a background of severe mucosal atrophy is quite difficult, even with ME/NBI\(^{[41-43]}\). Therefore, larger ER safety margins may be necessary if early-stage SRCs are surrounded by mucosa exhibiting atrophy or intestinal metaplasia, which often spreads subepithelially to the margins\(^{[40]}\).

Thus, to be curatively resected by ER in UD-EGC, it is important to consider the biological characteristics of UD-EGC and not simply to perform advanced endoscopy such as ME with NBI. Again, UD-EGC differs from D-EGC\(^{[6]}\).

Undifferentiated histology is the principal risk factor for the presence of residual tumor cells after complete resection of EGC\(^{[44]}\). PDA, SRC, and a minimum lateral safety margin of < 3 mm are significantly associated with residual tumors\(^{[44]}\). Short-term endoscopic follow-up with close examination of the resected base may reveal a residual tumor although CR of UD-EGC is histologically evident\(^{[44]}\).

A negative lateral margin (i.e., a margin free of cancerous cells) is very important in the context of CR. However, no consensus has emerged on the extent of this margin. A lateral margin of > 3 mm may increase the success rate of CR\(^{[44]}\). Further studies of patients with PDA and SRC are required.

Figure 5 showed a suggested decision algorithm for ER of UD-EGC.

### ADDITIVE TREATMENT AFTER NON-CR OF UD-EGC

The poorer CR rates of UD-EGC\(^{[6,10,29,30,32-34]}\) than D-EGC suggest that additive treatments may be required after ER. Residual cancer cells and LNM were evident
in surgical specimens of 50% and 13% of patients, respectively, when additive surgery was required because CR had failed\textsuperscript{6,10,30,45}. Undifferentiated histology was the principal risk factor for residual tumor cells after histologically complete resection\textsuperscript{44}. Thus, additional surgery may be appropriate after ER of UD-EGC. Hybrid natural orifice transluminal endoscopic surgery may be a good option for additional treatment after non-CR of UD-EGC. However, further work is necessary.

**CONCLUSION**

A low CR rate does not indicate that ER of UD-EGC...
should not be considered. The literature shows that patients who achieve CR after ER enjoy excellent survival outcomes. Furthermore the quality of life after stomach preservation is good. However, the biological behaviors of UD-EGC and D-EGC differ. Thus, decisions of ER in UD-EGC must be made very carefully, employing strict criteria based on the unique biological features of UD-EGC.

REFERENCES


Kim JH. Early gastric cancer with undifferentiated histology


P- Reviewer: Novotny AR  S- Editor: Ma YJ  L- Editor: A  E- Editor: Zhang DN